Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels.
Alberti
Alfredo
A
Department of Clinical and Experimental Medicine, Venetian Institute of Molecular Medicine, University of Padova, Via Giustiniani, no 2, 35128 Padua, Italy. alfredo.alberti@unipd.it
D000410:Alanine Transaminase / Q000097:blood*; D000998:Antiviral Agents / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology; D012016:Reference Values; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D012254:Ribavirin; D000410:Alanine Transaminase